NCT06057051Recruiting
Glaukos® iStent Infinite Trabecular Micro-Bypass System in Subjects With Mild to Moderate Primary Open-angle Glaucoma
A Prospective, Multicenter Study of the Glaukos® iStent Infinite Trabecular Micro-Bypass System Model iS3 in Subjects With Mild to Moderate Primary Open-angle Glaucoma
Source: ClinicalTrials.gov · Last updated 28 Sept 2023 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Prospective, multicenter, single-arm study of the iStent infinite in adult pseudophakic or phakic subjects with mild to moderate primary open angle glaucoma who have not failed conventional medical and surgical treatment
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 245 (estimated)
- First submitted
- 21 Sept 2023
- Start date
- 1 Sept 2023
- Primary completion date
- Aug 2025
- Lead sponsor
- Glaukos Corporation
- Diseases
- Glaucoma
- NCT number
- NCT06057051
What you commit to
- Study type: Interventional
- Planned participants: 245
- From 1 Sept 2023 to the primary completion date, Aug 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- glaucoma associated with vascular disorders
- Retinal disorders not associated with glaucoma
Other
- Traumatic, uveitic, neovascular, angle-closure glaucoma or
- Active corneal inflammation or edema
Who the study is looking for
- Diagnosis of primary open-angle glaucoma
- Phakic or pseudophakic
- Age 35 years or older
Age in the registry: 35 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| - Coordinator of this site? Confirm its status | Cincinnati | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.